NOVA.STU Novo Nordisk A/S
- Market cap
- -
- P/E
- 10.2x
- P/B
- 5.33x
- ROE
- 62.9%
- Dividend yield
- 2.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NOVA.STU undervalued?
Graham numberThe Graham number of Novo Nordisk A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novo Nordisk A/S fundamental analysis
No fundamental analysis for Novo Nordisk A/S yet.
Novo Nordisk A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Novo Nordisk A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novo Nordisk A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 112B | 127B | 127B | 141B | 177B | 232B | 290B | 309B | 351B |
| Gross Profit | 94.2B | 106B | 106B | 117B | 149B | 196B | 246B | 250B | 289B |
| Operating Income | 47.2B | 54.9B | 54.1B | 58.6B | 74.8B | 103B | 128B | 128B | 173B |
| EBITDA | 51.6B | 54.4B | 59.3B | 67.6B | 76.8B | 115B | 137B | 149B | 195B |
| Net Income | 38.6B | 41.4B | 42.1B | 47.8B | 55.5B | 83.7B | 101B | 102B | 139B |
| EPS | 16 | 8.63 | 8.97 | 10 | 12 | 19 | 23 | 23 | 31 |
| Balance Sheet | |||||||||
| Total Assets | 111B | 126B | 145B | 195B | 241B | 314B | 466B | 543B | 595B |
| Total Liabilities | 58.9B | 68.0B | 81.6B | 124B | 158B | 208B | 322B | 349B | 374B |
| Shareholders' Equity | 51.8B | 57.6B | 63.3B | 70.7B | 83.5B | 107B | 143B | 194B | 221B |
| Cash & Short-term Investments | 15.6B | 15.5B | 12.8B | 10.7B | 12.7B | 14.4B | 15.7B | 26.5B | 44.5B |
| Cash Flow | |||||||||
| Operating Cash Flow | 44.6B | 56.1B | 52.0B | 55.0B | 78.9B | 109B | 121B | 119B | 159B |
| Capital Expenditure | 12.4B | 8.51B | 22.1B | 7.39B | 14.8B | 38.9B | 51.3B | 90.1B | 49.7B |
| Free Cash Flow | 32.2B | 47.6B | 29.9B | 47.6B | 64.1B | 70.0B | 69.7B | 29.0B | 109B |
| Ratios | |||||||||
| ROE | 74.5% | 71.9% | 66.5% | 67.5% | 66.5% | 78.5% | 70.4% | 52.8% | 62.9% |
| ROA | 34.9% | 33.0% | 29.1% | 24.6% | 23.0% | 26.6% | 21.7% | 18.9% | 23.4% |
| Net Profit Margin | 34.5% | 32.7% | 33.2% | 33.9% | 31.4% | 36.0% | 34.8% | 33.1% | 39.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Novo Nordisk A/S dividends
- Dividend yield
- 2.19%
- Forward dividend
- -
- Payout ratio
- 50.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | DKK 51.8B | 12 | 50.5% |
| 2024 | DKK 44.1B | 9.94 | 43.7% |
| 2023 | DKK 31.8B | 7.13 | 38.0% |
| 2022 | DKK 25.3B | 5.62 | 45.6% |
| 2021 | DKK 21.5B | 4.66 | 45.1% |
| 2020 | DKK 20.1B | 4.28 | 47.8% |
| 2019 | DKK 19.7B | 4.09 | 47.4% |
| 2018 | DKK 19.0B | 7.77 | 49.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 20, 2023.
Who owns Novo Nordisk A/S
Ownership data of Novo Nordisk A/S is not available yet.
Novo Nordisk A/S company profile
- Company name
- Novo Nordisk A/S
- Ticker
- NOVA.STU
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -